Suggested remit: To appraise the clinical and cost effectiveness of sugemalimab within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
 
Status Awaiting development
Decision None selected
Process TAG
ID number 4001

Project Team

Project lead Celia Mayers

Email enquiries

Stakeholders

Companies sponsors • EQRx (sugemalimab)
Others • Department of Health and Social Care
  • NHS England
  • Welsh Government
Patient carer groups • Roy Castle Lung Cancer Foundation
Professional groups • Association of Cancer Physicians
  • British Thoracic Oncology Group
  • British Thoracic Society
  • Cancer Research UK
  • Royal College of Physicians
  • Royal College of Radiologists
Comparator companies • Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (confidentiality agreement not signed, not participating)
  • Aspire Pharma (pemetrexed) (confidentiality agreement not signed, not participating)
  • Celgene (paclitaxel) (confidentiality agreement not signed, not participating)
  • Eli Lilly (pemetrexed)
  • Genus Pharmaceuticals (bevacizumab, pemetrexed) (confidentiality agreement not signed, not participating)
  • Hospira (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  • Medac GmbH (vinorelbine)
  • Merck, Sharp & Dohme (pembrolizumab)
  • Organon Pharma (bevacizumab) (confidentiality agreement not signed, not participating)
  • Pfizer (bevacizumab)
  • Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  • Roche (atezolizumab, bevacizumab) (confidentiality agreement not signed, not participating)
  • Sandoz (cisplatin, pemetrexed) (confidentiality agreement not signed, not participating)
  • Sanofi (cemiplimab)
  • Seacross Pharmaceuticals (docetaxel, paclitaxel, pemetrexed) (confidentiality agreement not signed, not participating)
  • Sun Pharma (gemcitabine, pemetrexed) (confidentiality agreement not signed, not participating)
  • Teva UK (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)
  • Zentiva Pharma UK (bevacizumab, pemetrexed) (confidentiality agreement not signed, not participating)
General commentators • All Wales Therapeutics and Toxicology Centre
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Scottish Medicines Consortium
  • Welsh Health Specialised Services Committee
Relevant research groups • Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 December 2021 Invitation to participate
06 October 2021 - 27 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual